Product Description
For Major Depressive Disorder
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sunshine Lake Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Depressive Disorder, Major
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HEC113995-P-5 | P3 |
Unknown status |
Depressive Disorder, Major |
2024-04-01 |
95% |
| HEC113995-P-04/CRC-C2006 | P1 |
Completed |
Depressive Disorder, Major |
2020-08-12 |
45% |
| HEC113995PA•H2O-P-01/CRC-C1910 | P1 |
Completed |
Depressive Disorder, Major |
2019-12-06 |
45% |
| CTR20211474 | N/A |
Recruiting |
Depressive Disorder |
None |